Researchers have created a miniature laboratory platform that mimics head and neck cancer in a controlled human-like environment, allowing them to study how tumours grow and test potential treatments. The work, published in Proceedings of the National Academy of Sciences (PNAS), was led by a team at Politecnico di Milano's Department of Electronics, Information and Bioengineering, headed by Marco Rasponi, according to a university announcement.

The device, known as an organ-on-a-chip, reproduces head and neck squamous cell carcinoma (HNSCC) — the most common form of head and neck cancer — along with the blood vessels and nerves that surround it. This integration is key because cancer cells do not exist in isolation; they interact with nearby tissues, and those interactions can influence how the disease progresses and how patients respond to therapy.

“We designed a particularly complex chip, because these organ-on-a-chip models normally work with one or two cell types, whereas in this case we had four,” Rasponi explained in the release.

The platform was built using patient-derived tumour cells from Linköping University Hospital, along with cancer-associated fibroblasts, endothelial cells (which line blood vessels), and sensory neurons. These were cultured inside a specially engineered gel made from functionalised hyaluronic acid, which allowed the cells to organise into three-dimensional structures that resemble small tumour masses.

The research was a collaboration between Politecnico di Milano, Linköping University (particularly its Laboratory of Molecular Materials, m2Lab), the Department of Otorhinolaryngology of Region Östergötland in Sweden, and Northeast Ohio Medical University in the United States. The MiMic Lab research group at Politecnico developed the engineered model, while the Swedish partners handled the biological components.

The study’s first author is Alessia Maria Pignataro, a former Politecnico student now pursuing a PhD at Linköping University. The research originated from her Master’s thesis at the MiMic Lab. Alessandro Cordiale, a PhD candidate in the same research group, is also among the authors.

According to the university, the platform was built progressively: first integrating the tumour and vascular components, then adding the neural component, before optimising the complete system.

For university students studying biomedical engineering, bioengineering, or medicine, this work represents a tangible example of how advanced tissue engineering and microfluidics are converging to create tools that could one day replace animal models and enable personalised cancer care. The technology could allow doctors to test multiple drugs on a patient's own tumour cells in a dish before deciding on a treatment plan — a concept known as personalised medicine.

The simultaneous presence of tumour cells, blood vessels, and neurons on the chip makes it possible to investigate aspects of the disease that are difficult to study using traditional methods, including how cancer interacts with the nervous system and the biological mechanisms behind cancer-related pain.

Politecnico di Milano stated that the platform could, in the future, enable the development of patient-specific models to test different treatments and assess their responses, helping identify the most promising therapeutic strategies. It also offers a potential alternative to animal experimentation in biomedical research, supporting models that better represent the complexity of human tissues.

The result represents an advance in organ-on-a-chip technology and opens new opportunities for studying head and neck cancer and developing future personalised therapeutic approaches, according to the university.